B. Riley equity purchase facility
Company: Core Scientific
The claim, verbatim
Company entered into equity purchase agreement with B. Riley Principal Capital II giving right to sell up to $100,000,000 of common stock; $20.7 million net proceeds already drawn as of October 26, 2022
Source (primary)
Core Scientific 8-K filed 2022-10-27 (SEC EDGAR, sec_filing)
View cached copy (2026-09-13)Live source ↗
Quote: “On July 20, 2022, the Company entered into an equity purchase agreement with B. Riley Principal Capital II, pursuant to which the Company has the right to sell to B. Riley up to $100,000,000 of shares of the Company's common stock. As of October 26, 2022, the Company has sold 13,354,892 shares of common stock under B. Riley equity line of credit for net proceeds of approximately $20.7 million.”
How we checked this
Checked on September 22, 2026. The cited source supports every part of this claim.
The document confirms the $100,000,000 facility and the $20.7 million net proceeds drawn as of October 26, 2022.
Confirmed in the source:
- The Company entered into an equity purchase agreement with B. Riley Principal Capital II giving the right to sell up to $100,000,000 of common stock
- As of October 26, 2022, the Company had sold 13,354,892 shares for net proceeds of approximately $20.7 million
What we did: Read our cached copy of SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1839341/000119312522270236/d395956d8k.htm) in full (13,474 characters, retrieved September 13, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms Core Scientific 8-K filed 2022-10-27
Quote: “On July 20, 2022, the Company entered into an equity purchase agreement with B. Riley Principal Capital II, pursuant to which the Company has the right to sell to B. Riley up to $100,000,000 of shares of the Company's common stock. As of October 26, 2022, the Company has sold 13,354,892 shares of common stock under B. Riley equity line of credit for net proceeds of approximately $20.7 million.”